Passage: An experimental vaccine developed by GlaxoSmithKline that targets two viruses responsible for 70 percent of uterine cancer cases triggers twice the immune response in girls aged 10 to 14 than in those aged 15 to 24, the British pharmaceutical firm said Saturday. The results of phase 3 clinical trials were presented at an annual conference on infectious diseases under way this weekend in Washington.
conference